Elkington And Fife competitive analysis

Explore patent oppositions filed by Elkington And Fife against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 12, 2026
Patent NumberTitleApplicantOpposition Date
Crystalline Forms Of N-[4-(Chlorodifluoromethoxy)Phenyl]-6-[(3R)-3-Hydroxypyrrolidin-1-Yl]-5-(1H-Pyrazol-5-Yl)Pyridine-3-CarboxamideNOVARTISNov 5, 2026
Patch Product Based On Natural PolymersBAKELOct 21, 2026
Esketamine For The Treatment Of DepressionJANSSEN PHARMACEUTICAOct 6, 2026
Methods Of Reducing The Risk Of Cardiovascular Events In A SubjectAMARIN PHARMACEUTICALS IRELANDSep 30, 2026
Methods Of Reducing The Risk Of Cardiovascular Events In A SubjectAMARIN PHARMACEUTICALS IRELANDSep 30, 2026
Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin CompoundCORCEPT THERAPEUTICS INCORPORATEDSep 2, 2026
Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or HyperglycemiaBOEHRINGER INGELHEIMAug 26, 2026
Aqueous Formulation Comprising 1-(4-{[4-(Dimethylamino)Piperidin-1-Yl]Carbonyl}Phenyl)-3-[4-(4,6-Dimorpholin-4-Yl-1,3,5-Triazin-2-Yl)Phenyl]UreaPFIZERAug 16, 2026
Pharmaceutical Compositions Comprising CabotegravirVIIV HEALTHCAREJun 19, 2026
Connectors For Making Connections Between Analyte Sensors And Other DevicesABBOTT DIABETES CARE INC.Apr 16, 2026

Latest PTAB cases involving Elkington And Fife

Discover the latest PTAB cases involving Elkington And Fife, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Elkington And Fife with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 12, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ELKINGTON AND FIFE110 - - -
AMARIN PHARMACEUTICALS IRELAND - 24 - 1
F HOFFMANN LA ROCHE34238 - -
NOVARTIS12547 - 21